About Dr. Amit Patel I posted this on the "oth
Post# of 5066
Posted On: 10/20/2014 6:18:06 PM
About Dr. Amit Patel
I posted this on the "other" board. but wanted to post it here too.
http://www.biorestorative.com/content/scienti...sory-board
HMMMM....remember this PR about organ transplant?
a peek into the future perhaps? Good things still coming!
I posted this on the "other" board. but wanted to post it here too.
Quote:
Dr. Patel´s research includes studies in autologous stem cell therapy, researching the effects of stem cell transplantation in treating cardiomyopathy, limb ischemia (inadequate blood flow to the leg), and skin graft regeneration following burn injuries. Currently he is participating in a number of trials using autologous adult stem cells to treat cardiomyopathy and limb ischemia. In addition to cardiac research, his thoracic research includes cancer stem cell identification and destruction, as well as novel agents to selectively attack lung cancer, thoracic sarcoma, and metastatic diseases. His clinical interests include heart surgery for coronary disease, valve repair and replacement, heart failure, aortic surgery and stent grafts.
http://www.biorestorative.com/content/scienti...sory-board
HMMMM....remember this PR about organ transplant?
Quote:
"Although Regen's focus with Dr. Min is the development of technology licensed from Benitec BioPharma to stimulate the immune system, in the form of dCellVax, the current publication illustrates the broad applicability of gene silencing technology, not only for immune stimulation, but also for targeted immune suppression," said Dr. Thomas Ichim, Chief Scientific Officer of Regen BioPharma. "In the case of dCellVax we are blocking immune suppressive genes to induce immune stimulation, whereas in this case, we silenced immune stimulatory genes to block only the part of the immune system that is responsible for rejection of heart transplants."
Organ transplants are the only available cure for end stage organ failure conditions such as heart, liver, and kidney failure. Although conventional immune suppressants are effective at blocking initial rejection of the transplanted organ, chronic usage of immune suppressants is associated with increased infections and incidence of cancer. This is because current drugs to treat transplant rejection globally suppress the immune system, making the body more susceptible to pathogens and cancer. In contrast, the approach described in the current publication selectively blocks the immune system from killing the transplanted heart, while allowing other components of the immune system to function normally.
a peek into the future perhaps? Good things still coming!
(0)
(0)